Chloe Ferro (SheMed)

Overview

Chloe Ferro is the Co-Founder and President of SheMed, a rapidly growing health-tech company founded in 2024 with a focus on personalized healthcare solutions for women. Based in London, SheMed provides medically supervised GLP-1 treatment programs designed to tailor weight management solutions specifically for women. The company has rapidly attained unicorn status, reaching a valuation of $1 billion following a $50 million Series A funding round. This success underscores its pivotal role in addressing longstanding gaps in women's healthcare.

Recent Developments

Over the past two years, Chloe Ferro and SheMed have achieved several significant milestones.

October 2025: SheMed raised $50 million in Series A funding, reaching a valuation of $1 billion and officially becoming a unicorn company. This funding aims to expand UK operations, scale medical and technology teams, and enhance clinical infrastructure.
August 2025: SheMed established a partnership with Tasso, Inc. to integrate at-home blood tests into its services. This initiative aims to improve access to preventative care for women by removing logistical barriers associated with traditional blood tests.
Early 2025: SheMed was shortlisted for the "New Business of the Year" award at the British Business Excellence Awards, recognizing its rapid growth and innovative approach to women's healthcare.
January 2025: As a co-founder, Chloe Ferro celebrated the remarkable growth of SheMed, which expanded its membership to over 60,000 women seeking tailored healthcare treatments.

Personal Information

Attribute	Information
Full Name	Chloe Ferro
Nationality	British
Occupation	Co-Founder and President of SheMed
Known For	Co-founding the women's health company SheMed
Education	Information not explicitly stated

Early Life and Education

Chloe Ferro grew up in a family that was highly engaged with healthcare innovation and digital technology. This environment fostered her entrepreneurial spirit and commitment to improving healthcare outcomes. Together with her sister Olivia Ferro, Chloe co-founded SheMed with a vision to transform women's healthcare, leveraging their family background in health tech. Although specific details about Chloe's educational background are sparse, it is evident that both sisters garnered significant insights from their upbringing and practical experiences, fueling their drive to establish a company like SheMed.

Career and Notable Achievements

Chloe Ferro's professional journey has largely revolved around her pivotal role in building and leading SheMed.

2024: Chloe co-founded SheMed, focusing on addressing gaps in women's healthcare through the introduction of GLP-1 treatment programs.
2025: As President of SheMed, Chloe oversaw the company's expansion to a member base exceeding 60,000 women and helped secure a significant funding round, driving the company's valuation into unicorn status.
Key Achievements:
- Secured a €43 million funding round in early 2025 to scale services and enhance research capabilities.
- Launched collaborative partnerships to improve patient access, including at-home blood testing solutions with Tasso, Inc.

Current Work and Impact

Currently, Chloe Ferro, through her leadership at SheMed, is actively engaging in expanding the company’s reach across the UK and beyond. Her efforts are primarily centered on enhancing research into women's hormonal and metabolic health, driving innovation in personalized healthcare. SheMed's impact is significant as it introduces nuanced weight management solutions, which have traditionally bypassed many specifics of female health considerations, such as the need for more personalized GLP-1 medications for weight loss.

Conclusion

Chloe Ferro's work with SheMed is profoundly reshaping the landscape of women's healthcare by providing personalized, evidence-based solutions. Her journey highlights the vital steps necessary to address widely overlooked areas in health services designed for women. The growth of SheMed not only underscores the demand for more personalized and comprehensive healthcare solutions but also marks an important shift toward inclusive care models that empower women with better health outcomes. Chloe continues to be a pivotal force in driving SheMed's mission forward, underscoring the potential for further advancements and breakthroughs in women's health in future years.